Case Report
Published on 04 Mar 2024
Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction
in Cancer Immunity and Immunotherapy
- 1,990 views
- 1 citation
Case Report
Published on 04 Mar 2024
in Cancer Immunity and Immunotherapy
Review
Published on 27 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 27 Feb 2024
in Cancer Immunity and Immunotherapy
Correction
Published on 27 Feb 2024
in Cancer Immunity and Immunotherapy
Review
Published on 26 Feb 2024
in Cancer Immunity and Immunotherapy
Mini Review
Published on 26 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 23 Feb 2024
in Cancer Immunity and Immunotherapy
Brief Research Report
Published on 21 Feb 2024
in Cancer Immunity and Immunotherapy
Editorial
Published on 20 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 20 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 15 Feb 2024
in Cancer Immunity and Immunotherapy
Study Protocol
Published on 12 Feb 2024
in Cancer Immunity and Immunotherapy
Case Report
Published on 12 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 08 Feb 2024
in Cancer Immunity and Immunotherapy
Review
Published on 07 Feb 2024
in Cancer Immunity and Immunotherapy
Original Research
Published on 05 Feb 2024
in Cancer Immunity and Immunotherapy